Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ofranergene obadenovec - VBL Therapeutics

Drug Profile

Ofranergene obadenovec - VBL Therapeutics

Alternative Names: GT-111; VB 111

Latest Information Update: 17 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vascular Biogenics
  • Developer Gynecologic Oncology Group; Massachusetts General Hospital; VBL Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Angiogenesis modulating agents; Gene expression modulators; Gene transference; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glioblastoma; Ovarian cancer
  • Phase II Thyroid cancer
  • Preclinical Lung cancer; Malignant melanoma

Most Recent Events

  • 06 Nov 2019 US FDA approves IND application for VB 111 in Glioblastoma
  • 01 Nov 2019 Dana-Farber Cancer Institute files an IND application with the US FDA in USA for Glioblastoma, before November 2019
  • 03 Jun 2019 VBL therapeutics initiates enrolment in an investigator-sponsored trial for Glioblastoma (Recurrent) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top